A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds

Abstract

Ovarian cancer (OC) is a serious condition that often presents at advanced stages and has high mortality rates, with the current mode of early-stage screening lacking sensitivity and specificity. OC often presents asymptomatically, which renders early diagnosis difficult. Furthermore, many patients lack significant risk factors or family history of the disease. Five-year survival rates differ between patients with OC among racial, ethnic, and social groups as a result of different social barriers. This review article aims to present the currently existing data regarding health care disparities among OC patients of different ethnic, demographic, and socioeconomic backgrounds, and what next steps should be taken to better understand and eventually eliminate these potentially devastating health care disparities. Increasing data support the notion that a combination of genomic, socioeconomic status, social factors, and cultural differences lead to differential treatments and therefore health care disparities. While genomic and biological factors are important, language barriers, geographic and travel barriers, differences in comorbidity likelihood between populations, and different treatment plans seem to have a greater impact on 5-year survival rates of patients from diverse backgrounds. Language barriers limit a shared-decision model of care. Transportation limitations and geographic differences can lead to limited follow-up and insufficient care in resource and equipment restrictive settings. Patients with these barriers also tend to have a higher incidence of comorbidities that raise the mortality rate of OC. Further research needs to explore effective solutions to bridge health care disparities and understand why they occur.

Keywords

Ovarian cancer / healthcare disparities / public health / racial disparities / epidemiology / literature review

References

[1] Randall TC.Health care disparities in hereditary ovarian cancer: are we reaching the underserved population?.Curr Treat Options Oncol2016;17:39

[2] Schorge JO,Coleman RL,Kauff ND.SGO White Paper on ovarian cancer: etiology, screening and surveillance..Gynecol Oncol2010;119:7-17

[3] Siegel RL,Jemal A.Cancer statistics, 2017..CA Cancer J Clin2017;67:7-30

[4] Dutta S,Phalen A.Biomarkers for ovarian cancer detection and therapy..Cancer Biol Ther2010;9:668-77

[5] Cohen JG,Cruz A.In 2014, can we do better than CA125 in the early detection of ovarian cancer?.World J Biol Chem2014;5:286-300 PMCID:PMC4160523

[6] Brain KE,Simon AE,Roberts C.Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample..BMC Cancer2014;14:171 PMCID:PMC3975332

[7] Eisenhauer EA.Real-world evidence in the treatment of ovarian cancer..Ann Oncol2017;

[8] Buys SS,Black A,Lamerato L.Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized trial..JAMA2011;305:2295-303

[9] Chien J.Ovarian cancer prevention, screening, and early detection: report from the 11th biennial ovarian cancer research symposium..Int J Gynecol Cancer2017;27:S20-2 PMCID:PMC6154781

[10] Rauh-Hain JA,Del Carmen MG.Ovarian cancer screening and early detection in the general population..Rev Obstet Gynecol2011;4:15-21 PMCID:PMC3100094

[11] Nagle CM.Schwab M.Ovarian cancer epidemiology..Encyclopedia of cancer.2011;Berlin, HeidelbergSpringer

[12] Lowe KA,Taylor A,Kelsh M.An international assessment of ovarian cancer incidence and mortality..Gynecol Oncol2013;130:107-14

[13] Teixeira N,Vos JR,Jansen L.Ovarian cancer in BRCA1/2 mutation carriers: the impact of mutation position and family history on the cancer risk..Maturitas2015;82:197-202

[14] Reid BM,Sellers TA.Epidemiology of ovarian cancer: a review..Cancer Biol Med2017;14:9-32 PMCID:PMC5365187

[15] Collins Y,Chapman-Davis E,Farley JH.Gynecologic cancer disparities: a report from the health disparities taskforce of the society of gynecologic oncology..Gynecol Oncol2014;133:353-61 PMCID:PMC4079541

[16] Srivastava SK,Miree O,Singh S.Racial health disparities in ovarian cancer: not just black and white..J Ovarian Res2017;10:58 PMCID:PMC5607508

[17] Howell EA,Hayes MP,Franco R.Racial disparities in the treatment of advanced epithelial ovarian cancer..Obstet Gynecol2013;122:1025-32 PMCID:PMC3840948

[18] Bownes LV,Maizlin II,Gow KW.Socioeconomic disparities affect survival in malignant ovarian germ cell tumors in AYA population..J Surg Res2018;222:180-6 PMCID:PMC5742061

[19] Sakhuja S,Pisu M.Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites..J Ovarian Res2017;10:57 PMCID:PMC5568254

[20] Cragun D,Lewis C,Kim J.Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors..Cancer2017;123:2497-505 PMCID:PMC5474124

[21] Nelson HD,Zakher B,Okinaka-Hu L.Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force Recommendation..Ann Intern Med2014;160:255-66

[22] Eccles DM,Monteiro AN,Couch FJ.BRCA1 and BRCA2 genetic testing- pitfalls and recommendations for managing variants of uncertain clinical significance..Ann Oncol2015;26:2057-65 PMCID:PMC5006185

[23] Winters S,Murphy D.Breast cancer epidemiology, prevention, and screening..Prog Mol Biol Transl Sci2017;151:1-32

[24] Jones T,Kim Y.Predictors of BRCA1/2 genetic testing among black women with breast cancer: a population-based study..Cancer Med2017;6:1787-98 PMCID:PMC5504315

[25] Churpek JE,Zheng Y,Thornton AM.Inherited predisposition to breast cancer among African American women..Breast Cancer Res Treat2015;149:31-9 PMCID:PMC4298662

[26] Ricks-Santi L,Gold B,Thompson N.Next generation sequencing reveals high prevalence of BRCA1 and BRCA2 variants of unknown significance in early-onset breast cancer in African American women..Ethn Dis2017;27:169-78 PMCID:PMC5398176

[27] Bandera EV,Rodriguez-Rodriguez L,Kushi LH.Racial/ethnic disparities in ovarian cancer treatment and survival..Clin Cancer Res2016;22:5909-14 PMCID:PMC5135649

[28] Bandera EV,Moorman PG,Barnholtz-Sloan JS.Obesity, weight gain, and ovarian cancer risk in African American women..Int J Cancer2016;139:593-600 PMCID:PMC4982766

[29] Chatterjee S,Caputo TA.Disparities in gynecological malignancies..Front Oncol2016;6:36 PMCID:PMC4761838

[30] Liu Z,Zhao JJ,Du P.The association between overweight, obesity and ovarian cancer: a meta-analysis..Jpn J Clin Oncol2015;45:1107-15

[31] Olsen CM,Whiteman DC,Kolahdooz F.Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis..Eur J Cancer2007;43:690-709

[32] Calle EE,Walker-Thurmond K.Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults..N Engl J Med2003;348:1625-38

[33] Choi EK,Lee KH,Eisenhut M.Body mass index and 20-specific cancers: re-analyses of dose-response meta-analyses of observational studies..Ann Oncol2018;29:749-57

[34] Clarke P,Johnston LD.Social disparities in BMI trajectories across adulthood by gender, race/ethnicity and lifetime socio-economic position: 1986-2004..Int J Epidemiol2009;38:499-509 PMCID:PMC2663716

[35] Erondu CO,Bandera EV,Bondy M.The association between body mass index and presenting symptoms in African American women with ovarian cancer..J Womens Health (Larchmt)2016;25:571-8 PMCID:PMC4900212

[36] Schwei RJ,Ejebe I,Park L.Limited English proficient patients’ perceptions of when interpreters are needed and how the decision to utilize interpreters is made..Health Commun2018;33:1503-8 PMCID:PMC5860946

[37] Flores G,Barone CP,Lin H.Errors of medical interpretation and their potential clinical consequences: a comparison of professional versus ad hoc versus no interpreters..Ann Emerg Med2012;60:545-53

[38] Kamara D,Youngblom J,Joseph G.Cancer counseling of low-income limited English proficient Latina women using medical interpreters: implications for shared decision-making..J Genet Couns2018;27:155-68

[39] Lee JS,Mutha S,Gregorich SE.Hospital discharge preparedness for patients with limited English proficiency: a mixed methods study of bedside interpreter-phones..Patient Educ Couns2018;101:25-32 PMCID:PMC5732033

[40] Bond J,Nassrally SM.The role of ad-hoc interpreters in teaching communication skills with ethnic minorities..Med Teach2012;34:81-2

[41] Syed ST,Sharp LK.Traveling towards disease: transportation barriers to health care access..J Community Health2013;38:976-93 PMCID:PMC4265215

[42] Tan W,Carter RL.Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001..Gynecol Oncol2009;114:346-52

[43] Guidry JJ,Zhang D.Transportation as a barrier to cancer treatment..Cancer Pract1997;5:361-6

[44] Bristow RE,Ziogas A.Adherence to treatment guidelines for ovarian cancer as a measure of quality care..Obstet Gynecol2013;121:1226-34

[45] Scalici J,Black J,Nicolson W.Minority participation in gynecologic oncology group (GOG) studies..Gynecol Oncol2015;138:441-4 PMCID:PMC4670048

[46] Armstrong J,Kotchko N,Schwartz MD.Utilization and outcomes of BRCA genetic testing and counseling in a National commercially insured population: the ABOUT study..JAMA Oncol2015;1:1251-60

[47] Peres LC,Abbott SE,Bandera EV.Analgesic medication use and risk of epithelial ovarian cancer in African American women..Br J Cancer2016;114:819-25 PMCID:PMC4984862

[48] Qato DM,Conti RM,Alexander GC.Racial and ethnic disparities in cardiovascular medication use among older adults in the United States..Pharmacoepidemiol Drug Saf2010;19:834-42 PMCID:PMC3586253

[49] Dehlendorf C,de Bocanegra HT,Bradsberry M.Race, ethnicity and differences in contraception among low-income women: methods received by family PACT clients, California, 2001-2007..Perspect Sex Reprod Health2011;43:181-7 PMCID:PMC3412526

[50] Sarrazin MS,Richardson KK.Racial segregation and disparities in healthcare delivery: conceptual model and empirical assessment..Health Serv Res2009;44:1424-44 PMCID:PMC2739036